231 related articles for article (PubMed ID: 10799742)
41. Oltipraz chemoprevention trial in Qidong, Jiangsu Province, People's Republic of China.
Zhang BC; Zhu YR; Wang JB; Wu Y; Zhang QN; Qian GS; Kuang SY; Li YF; Fang X; Yu LY; De Flora S; Jacobson LP; Zarba A; Egner PA; He X; Wang JS; Chen B; Enger CL; Davidson NE; Gordon GB; Gorman MB; Prochaska HJ; Groopman JD; Muñoz A; Kensler TW
J Cell Biochem Suppl; 1997; 28-29():166-73. PubMed ID: 9589363
[TBL] [Abstract][Full Text] [Related]
42. Enhancement of biliary excretion of aflatoxin B(1) and suppression of hepatic ornithine decarboxylase activity by 2-(allylthio)pyrazine in rats.
Ha TG; Mar WC; Kim SG; Surh YJ; Kim ND
Mutat Res; 1999 Jul; 428(1-2):59-67. PubMed ID: 10517979
[TBL] [Abstract][Full Text] [Related]
43. Alteration of p53 and p21 during hepatocarcinogenesis in tree shrews.
Su JJ; Ban KC; Li Y; Qin LL; Wang HY; Yang C; Ou C; Duan XX; Lee YL; Yang RQ
World J Gastroenterol; 2004 Dec; 10(24):3559-63. PubMed ID: 15534906
[TBL] [Abstract][Full Text] [Related]
44. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
45. Differential expression of genes during aflatoxin B(1)-induced hepatocarcinogenesis in tree shrews.
Li Y; Wan DF; Su JJ; Cao J; Ou C; Qiu XK; Ban KC; Yang C; Qin LL; Luo D; Yue HF; Zhang LS; Gu JR
World J Gastroenterol; 2004 Feb; 10(4):497-504. PubMed ID: 14966905
[TBL] [Abstract][Full Text] [Related]
46. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes.
Jacobson LP; Zhang BC; Zhu YR; Wang JB; Wu Y; Zhang QN; Yu LY; Qian GS; Kuang SY; Li YF; Fang X; Zarba A; Chen B; Enger C; Davidson NE; Gorman MB; Gordon GB; Prochaska HJ; Egner PA; Groopman JD; Muñoz A; Helzlsouer KJ; Kensler TW
Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):257-65. PubMed ID: 9107431
[TBL] [Abstract][Full Text] [Related]
47. Quantification of aflatoxin-B1-N7-Guanine in human urine by high-performance liquid chromatography and isotope dilution tandem mass spectrometry.
Egner PA; Groopman JD; Wang JS; Kensler TW; Friesen MD
Chem Res Toxicol; 2006 Sep; 19(9):1191-5. PubMed ID: 16978023
[TBL] [Abstract][Full Text] [Related]
48. Human hepatitis B virus and hepatocellular carcinoma. II. Experimental induction of hepatocellular carcinoma in tree shrews exposed to hepatitis B virus and aflatoxin B1.
Yan RQ; Su JJ; Huang DR; Gan YC; Yang C; Huang GH
J Cancer Res Clin Oncol; 1996; 122(5):289-95. PubMed ID: 8609152
[TBL] [Abstract][Full Text] [Related]
49. Development of aflatoxin B(1)-lysine adduct monoclonal antibody for human exposure studies.
Wang JS; Abubaker S; He X; Sun G; Strickland PT; Groopman JD
Appl Environ Microbiol; 2001 Jun; 67(6):2712-7. PubMed ID: 11375185
[TBL] [Abstract][Full Text] [Related]
50. Modulation of aflatoxin biomarkers in human blood and urine by green tea polyphenols intervention.
Tang L; Tang M; Xu L; Luo H; Huang T; Yu J; Zhang L; Gao W; Cox SB; Wang JS
Carcinogenesis; 2008 Feb; 29(2):411-7. PubMed ID: 18192689
[TBL] [Abstract][Full Text] [Related]
51. Oltipraz: a laboratory and clinical review.
Benson AB
J Cell Biochem Suppl; 1993; 17F():278-91. PubMed ID: 8412206
[TBL] [Abstract][Full Text] [Related]
52. Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms.
Eaton DL; Bammler TK; Kelly EJ
Adv Exp Med Biol; 2001; 500():559-76. PubMed ID: 11764998
[TBL] [Abstract][Full Text] [Related]
53. Aflatoxin-albumin adduct formation after single and multiple doses of aflatoxin B(1) in rats treated with Thai medicinal plants.
Vinitketkumnuen U; Chewonarin T; Dhumtanom P; Lertprasertsuk N; Wild CP
Mutat Res; 1999 Jul; 428(1-2):345-51. PubMed ID: 10518006
[TBL] [Abstract][Full Text] [Related]
54. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer.
Egner PA; Wang JB; Zhu YR; Zhang BC; Wu Y; Zhang QN; Qian GS; Kuang SY; Gange SJ; Jacobson LP; Helzlsouer KJ; Bailey GS; Groopman JD; Kensler TW
Proc Natl Acad Sci U S A; 2001 Dec; 98(25):14601-6. PubMed ID: 11724948
[TBL] [Abstract][Full Text] [Related]
55. Oltipraz chemoprevention trial in Qidong, People's Republic of China: unaltered oxidative biomarkers.
Glintborg B; Weimann A; Kensler TW; Poulsen HE
Free Radic Biol Med; 2006 Sep; 41(6):1010-4. PubMed ID: 16934685
[TBL] [Abstract][Full Text] [Related]
56. Effects of multiple risk factors for hepatocellular carcinoma on formation of aflatoxin B1-DNA adducts.
Yu MW; Lien JP; Liaw YF; Chen CJ
Cancer Epidemiol Biomarkers Prev; 1996 Aug; 5(8):613-9. PubMed ID: 8824363
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the post-initiation effects of oltipraz on aflatoxin B1-induced preneoplastic foci in a rat model of hepatic tumorigenesis.
Maxuitenko YY; MacMillan DL; Kensler TW; Roebuck BD
Carcinogenesis; 1993 Nov; 14(11):2423-5. PubMed ID: 8242875
[TBL] [Abstract][Full Text] [Related]
58. Use of aflatoxin adducts as intermediate endpoints to assess the efficacy of chemopreventive interventions in animals and man.
Kensler TW; Groopman JD; Roebuck BD
Mutat Res; 1998 Jun; 402(1-2):165-72. PubMed ID: 9675269
[TBL] [Abstract][Full Text] [Related]
59. Determinants of aflatoxin levels in Ghanaians: sociodemographic factors, knowledge of aflatoxin and food handling and consumption practices.
Jolly P; Jiang Y; Ellis W; Awuah R; Nnedu O; Phillips T; Wang JS; Afriyie-Gyawu E; Tang L; Person S; Williams J; Jolly C
Int J Hyg Environ Health; 2006 Jul; 209(4):345-58. PubMed ID: 16644281
[TBL] [Abstract][Full Text] [Related]
60. A review of molecular mechanisms in the development of hepatocellular carcinoma by aflatoxin and hepatitis B and C viruses.
Moudgil V; Redhu D; Dhanda S; Singh J
J Environ Pathol Toxicol Oncol; 2013; 32(2):165-75. PubMed ID: 24099430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
